Edition:
India

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.90USD
1:30am IST
Change (% chg)

$0.02 (+2.27%)
Prev Close
$0.88
Open
$0.93
Day's High
$0.93
Day's Low
$0.89
Volume
3,048
Avg. Vol
19,215
52-wk High
$4.59
52-wk Low
$0.84

Select another date:

Tue, Mar 6 2018

BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

* MABVAX THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT Source text for Eikon: Further company coverage:

BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075

* MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT

BRIEF-Barry Honig Reports 4.99 Pct Stake In MabVax Therapeutics

* BARRY HONIG REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12, 2018 - SEC FILING‍​

BRIEF-John Stetson Reports 4.99 Pct Stake In Mabvax Therapeutics Holdings

* JOHN STETSON REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12 - SEC FILING Source text: (http://bit.ly/2EoGXsh) Further company coverage:

BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873

* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER

BRIEF-Mabvax Therapeutics Holdings Provides Business Strategy Update

* MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE

Select another date: